Yancopoulos George's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 6, 2021
- Accession no.
- 0001708138-21-000044
- Filed
- Aug 6, 2021
- Trade date
- Jun 24-Aug 5, 2021
- Filing delay
- 43 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $30.0M. It was filed 43 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yancopoulos GeorgeCIK 0001226690 | Director, Officer (President and Chief Scientific) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 5, 2021 | Common Stock | SSaleDisposed | −50,000 | $600.06F2 | −$30,003,000 | 937,483 | Direct | |
| Jun 24, 2021 | Common Stock | GGiftAcquired | +211,585 | $0.00 | $0 | 213,693 | Indirect | |
| Jun 24, 2021 | Common Stock | GGiftDisposed | −211,585 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents volume-weighted average price of sales of 50,000 shares of Company stock on August 5, 2021 at prices ranging from $600.00 to $600.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 5, 2021 at each separate price.
Referenced by the price of 1 transaction in Table I.